Bill Ericson

Bill Ericson is a Founding Partner at Wildcat where he focuses on investments in artificial intelligence (AI), machine learning (ML) and enterprise SaaS as enablers of digital health, vertical apps, and enterprise and consumer communications. His specific areas of interest include improving the digital health ecosystem to deliver better, more efficient, healthcare, and the role data and machine intelligence can play in virtualizing processes in the healthcare market. Concurrently, he is a Managing Partner of Mohr Davidow Ventures, where he started his venture career.

The son of a Foreign Service officer, Bill grew up as a citizen of the world, living in England, Iceland, Korea and Japan, and learned to speak Japanese. Bill’s career role model is Bill Davidow, founder of Mohr Davidow Ventures, for his extraordinary humanity and remarkable business insights. In his spare time, Bill can be found playing electric guitar (wishing he could play like Derek Trucks), and cheering on the Golden State Warriors.

Bill has worked with technology entrepreneurs for his entire career, which spans more than two decades.  Trained in economics and law, Bill is keenly interested in how technology, social media and big data is transforming society and human interactions. In this light, Bill has contributed to a new curriculum on digital ethics for the Kennedy School of Ethics at his alma mater, Georgetown University. A former attorney, he was an early partner and founder of the Seattle office of Venture Law Group before joining Mohr Davidow Ventures, where he began his venture capital career.

Bill received his B.S.F.S. from Georgetown University School of Foreign Service and a J.D. from Northwestern University School of Law.

Investments:

• Bill’s current investments include Adamas Pharmaceuticals (NASDAQ: ADMS), Carrum Health, Clover Health, Employee Channel, Healthtap, Pacific Biosciences (NYSE: PACB), Reach, Splice Machine, what3words and WorkFusion.
• Bill’s prior investments include OpenDNS (acquired by Cisco), Parallele (acquired by Affymetrix), Sabrix (acquired by Thomson Reuters Corp), Rocket Fuel (NASDAQ: FUEL), Rosetta Inpharmatics (NASDAQ: RSTA, acquired by Merck), Sequenta (acquired by Adaptive Biotechnologies), Ticketfly (acquired by Pandora), and Verinata (acquired by Illumina).